Purchase this article with an account.
M. Gordon, V. Morales-Canton, A. Solis-Vivanco, M. A. Martinez-Castellanos, E. Reyna-Castelán, M. Hernandez-Rojas, N. Salazar-Teran, J. L. Guerrero-Naranjo, J. Fromow-Guerra, H. Quiroz-Mercado; Complication After Intravitreal Bevacizumab (Avastin): Analysis of 1910 Injections. Invest. Ophthalmol. Vis. Sci. 2007;48(13):88.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the ocular and systemic complications after intravitreal Bevacizumab (Avastin) injection
Retrospective study. We reviewed records of patients that were injected with 2,5 mg/0,1 ml of intravitreal Bevacizumab (Avastin) in a period of fourteen months in the Retina Service of Asociacion para Evitar la Ceguera en Mexico.
Records of 1910 injections were reviewed. Four patients (0.2%) with proliferative diabetic retinopathy developed tractional retinal detachment(TRD). Three cases(0.15%) of endophtalmitis , one rhegmatogenuos retinal detachmen (RRD)(0.05%), and one vitreous hemorrhage(VH) (0.05%) were also observed. No systemic effect was reported.
Out of 1910 injections our rate of ocular complications was 0,47%. (TRD, RRD, VH and endophthalmitis). No systemic complications were observed.
This PDF is available to Subscribers Only